Related Experiment Video
Updated: Apr 19, 2026
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
[Is there a place for surgical management in stage IIIA N2 non-small cell lung cancer?]
P-B Pagès1, A Pforr1, J-P Delpy1
1Service de chirurgie cardiovasculaire et thoracique, université de Bourgogne, CHU Bocage central, CHU de Dijon, BP 77908, 14, rue Gaffarel, 21079 Dijon cedex, France.
Introduction:
Non-small cell lung cancer (NSCLC) remains a major health problem, with a 5-year overall survival of 25%. Surgical management of stage IIIA NSCLC is still controversial. We conduct a systematic analysis of the different management strategies for stage IIIA-N2 NSCLC.
Methods:
We analyzed randomized control trials published between January 1990 to December 2013, comparing induction chemotherapy followed by surgery vs. surgery alone, and those comparing induction chemo or radiotherapy followed by surgery vs. induction chemotherapy followed by radiotherapy for stage IIIA-N2 NSCLC.
Results:
A 16% significant increase in overall survival was found in favor of induction chemotherapy followed by surgery vs. surgery alone. However, there was no significant difference in overall survival between induction chemo- or radiotherapy followed by surgery and induction chemotherapy followed by radiotherapy.
Conclusion:
Current scientific data do not permit the exclusion of surgery as an option in the management of stage IIIA-N2 NSCLC.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
07:30Electromagnetic Navigation Transthoracic Nodule Localization for Minimally Invasive Thoracic Surgery
Published on: May 4, 2022